Analysts Expect iTeos Therapeutics, Inc. (NASDAQ:ITOS) Will Announce Earnings of $1.20 Per Share

Wall Street analysts expect iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) to report earnings per share (EPS) of $1.20 for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for iTeos Therapeutics’ earnings. The lowest EPS estimate is $0.08 and the highest is $3.13. iTeos Therapeutics reported earnings of ($0.75) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 260%. The business is scheduled to report its next earnings report on Monday, January 1st.

On average, analysts expect that iTeos Therapeutics will report full-year earnings of $4.38 per share for the current financial year, with EPS estimates ranging from $1.72 to $12.33. For the next fiscal year, analysts expect that the business will post earnings of ($2.85) per share, with EPS estimates ranging from ($6.63) to $1.54. Zacks’ EPS averages are an average based on a survey of analysts that cover iTeos Therapeutics.

iTeos Therapeutics (NASDAQ:ITOS – Get Rating) last issued its quarterly earnings results on Thursday, May 12th. The company reported $1.82 EPS for the quarter, beating analysts’ consensus estimates of $0.80 by $1.02. The firm had revenue of $152.52 million for the quarter, compared to analysts’ expectations of $63.30 million.

Separately, Piper Sandler dropped their price target on iTeos Therapeutics from $42.00 to $34.00 in a research report on Wednesday, May 11th.

Shares of NASDAQ ITOS traded up $0.25 during trading on Friday, reaching $17.09. 387,888 shares of the stock traded hands, compared to its average volume of 517,149. iTeos Therapeutics has a 52-week low of $16.21 and a 52-week high of $52.43. The company has a 50-day moving average of $27.46 and a 200-day moving average of $33.92. The stock has a market capitalization of $607.40 million, a P/E ratio of 2.19 and a beta of 1.94.

In related news, major shareholder Boxer Capital, Llc sold 575,201 shares of the business’s stock in a transaction on Thursday, March 17th. The stock was sold at an average price of $35.25, for a total transaction of $20,275,835.25. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Yvonne Mcgrath sold 10,000 shares of the business’s stock in a transaction on Tuesday, March 1st. The shares were sold at an average price of $36.76, for a total value of $367,600.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,431,638 shares of company stock worth $40,058,468. 3.95% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its stake in iTeos Therapeutics by 106.5% in the 1st quarter. BlackRock Inc. now owns 3,331,313 shares of the company’s stock worth $107,203,000 after acquiring an additional 1,718,085 shares during the last quarter. RTW Investments LP increased its stake in iTeos Therapeutics by 37.1% in the 3rd quarter. RTW Investments LP now owns 2,353,015 shares of the company’s stock worth $63,531,000 after acquiring an additional 636,430 shares during the last quarter. State Street Corp increased its stake in iTeos Therapeutics by 124.3% in the 1st quarter. State Street Corp now owns 1,711,891 shares of the company’s stock worth $55,089,000 after acquiring an additional 948,540 shares during the last quarter. Vanguard Group Inc. increased its stake in iTeos Therapeutics by 39.1% in the 1st quarter. Vanguard Group Inc. now owns 1,476,042 shares of the company’s stock worth $47,499,000 after acquiring an additional 415,232 shares during the last quarter. Finally, EcoR1 Capital LLC increased its position in shares of iTeos Therapeutics by 25.8% during the 3rd quarter. EcoR1 Capital LLC now owns 1,303,157 shares of the company’s stock valued at $35,185,000 after purchasing an additional 267,293 shares during the last quarter. Institutional investors and hedge funds own 94.71% of the company’s stock.

About iTeos Therapeutics (Get Rating)

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

Featured Stories